Market in sight for Pharmaxis
Wednesday, 20 August, 2008
Pharmaxis [ASX: PXS] has concluded a Phase 3 clinical trial of its Bronchitol treatment, confirming its safety in subjects with bronchiectasis.
None of the 99 subjects who concluded the trial experienced serious adverse effects attributable to the drug, even after a 12-month treatment schedule.
Some minor side effects were attributable to the medication, such as coughing and a sore throat, but these symptoms occurred in less than 10 per cent of the sample group.
Seven subjects did drop out of the trial after suffering adverse events – lung infections or chronic coughing – but it has not been demonstrated that Bronchitol was the cause of these effects.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
